Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Riad Salem

Vascular & Interventional Radiology Chicago, IL Medical Doctor

NPI 1164447645 CMS profile 325093

680 N Lake Shore Dr, Suite 1000, Chicago, IL 60611

Open in the dashboard

General payments

$2,282,122

895 records reported · program years 2019–2025

Research payments

$32,188

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$173,003 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Riad Salem of Chicago, IL is reported in the CMS Open Payments database as having received $2,282,122 across 895 general payments and $32,188 in research payments paid to them. Separately, studies naming them as principal investigator received $173,003 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $555,008 156
2024 General $365,923 200
2023 General $370,388 181
2023 Research $19,550 1
2022 General $344,188 129
2021 General $215,235 74
2021 Research $2,110 2
2020 General $208,951 83
2019 General $222,429 72
2019 Research $10,528 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Riad Salem
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Riad Salem were reported at $555,008. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Riad Salem Vascular & Interventional Radiology median Middle half National median
2019 $222,429 $422 $125–$1,555 $163
2020 $208,951 $200 $68–$652 $114
2021 $215,235 $280 $99–$866 $132
2022 $344,188 $433 $137–$1,497 $149
2023 $370,388 $506 $152–$2,019 $160
2024 $365,923 $556 $175–$1,930 $164
2025 $555,008 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $842,935 331 payments
  2. Bard Peripheral Vascular, Inc. $398,872 145 payments
  3. Surefire Medical, Inc. $265,484 16 payments
  4. Biocompatibles, Inc. $151,474 10 payments
  5. Sirtex Medical Inc $138,660 34 payments
  6. Eisai Inc. $98,891 58 payments
  7. Siemens Medical Solutions USA, Inc. $81,737 108 payments
  8. AstraZeneca Pharmaceuticals LP $80,898 41 payments
  9. Cook Incorporated $69,705 18 payments
  10. Merck Sharp & Dohme Corporation $24,233 28 payments
  11. Other $129,234 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,490,378 289 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $365,923 70 payments
  3. Travel and Lodging $253,672 272 payments
  4. Acquisitions $123,728 2 payments
  5. Food and Beverage $22,679 251 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $10,895 2 payments
  7. Honoraria $10,888 6 payments
  8. Grant $3,500 1 payment
  9. Education $460 2 payments
Products named General payments · program years 2019–2025
  1. TheraSphere Y90 Glass Microspheres 10 GBq $446,076 133 payments
  2. TRINAV INFUSION SYSTEM $265,484 16 payments
  3. General - Therapies $178,224 23 payments
  4. THERASPHERE - BIO $151,487 11 payments
  5. SIR-Spheres Microspheres $138,660 34 payments
  6. Lenvima $98,856 57 payments
  7. TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) $57,045 26 payments
  8. IMFINZI $32,822 18 payments
  9. GENERAL PAIN MANAGEMENT $32,608 14 payments
  10. TECENTRIQ $28,227 17 payments
  11. Other $191,320 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Cook Incorporated $19,550 1 payment
  2. Bard Peripheral Vascular, Inc. $10,528 1 payment
  3. F. Hoffmann-La Roche AG $2,110 2 payments

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$39,737

Medicare's payments for the services billed

Medicare patients

165

Average age 69

Services billed

522

83 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 63%
Ischemic heart disease 50%
Heart failure 48%
Arthritis 48%
Diabetes 46%
Atrial fibrillation 38%
Cancer 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TECENTRIQ
$9,020 — —
Lenvima
$6,800 — —
IMFINZI
$2,376 — —
KEYTRUDA
$382 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

899 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record